Rationale and design of the DIPAK 1 study: a randomized controlled clinical trial assessing the efficacy of lanreotide to Halt disease progression in autosomal dominant polycystic kidney disease.

ABSTRACT:

Background

There are limited therapeutic options to slow the progression of autosomal dominant polycystic kidney disease (ADPKD). Recent clinical studies indicate that somatostatin analogues are promising for treating polycystic liver disease and potentially also for the kidney phenotype. We report on the design of the DIPAK 1 (Developing Interventions to Halt Progression of ADPKD 1) Study, which will examine the efficacy of the somatostatin analogue lanreotide on preservation of kidney function in ADPKD.

Study design

The DIPAK 1 Study is an investigator-driven, randomized, multicenter, controlled, clinical trial.

Setting & participants

We plan to enroll 300 individuals with ADPKD and estimated glomerular filtration rate (eGFR) of 30-60 mL/min/1.73 m(2) who are aged 1

SUBMITTER: Meijer E 

PROVIDER: S-EPMC4042404 | biostudies-literature | 2014 Mar

REPOSITORIES: biostudies-literature